ANSWER: B

Rationale:

This patient has a clear clinical indication for Gocovri (amantadine ER): functionally significant levodopa-induced dyskinesia, an FDA indication for which amantadine ER is the only specifically approved pharmacological agent, documented on both the UDysRS score and functional impairment in self-care tasks. The renal constraint is the critical prescribing decision point. His CrCl of 42 mL/min falls squarely in the 30 to 59 mL/min range specified in the Gocovri prescribing information as requiring a dose reduction: the maximum approved dose for this renal range is 68.5 mg once daily at bedtime, not the standard 137 mg target. This is not a contraindication — the drug can be used — but the dose ceiling is 68.5 mg, not 137 mg. The approved titration protocol additionally specifies initiating at 68.5 mg for the first week regardless of the target dose, providing a tolerability step before reaching the maintenance dose; in this patient with a renally adjusted ceiling of 68.5 mg, the titration step and the maintenance dose happen to coincide. Option B correctly applies both the renal dose ceiling and the titration protocol.

• Option A: Option A is incorrect; a renally adjusted dose of 68.5 mg is specifically approved in the prescribing information for CrCl 30 to 59 mL/min — deep brain stimulation referral is not the default next step when an approved pharmacological option exists.
• Option C: Option C is incorrect; the 30 mL/min threshold is the contraindication boundary, but a separate dose reduction requirement applies for CrCl 30 to 59 mL/min — exceeding the contraindication threshold does not mean no dose adjustment is required.
• Option D: Option D is incorrect; the combination of rasagiline and amantadine ER is not a listed contraindication in either prescribing document; amantadine's dopamine-releasing activity does not create a clinically meaningful serotonin syndrome risk with MAO-B inhibition at therapeutic doses.
• Option E: Option E is incorrect; the renal dose adjustment for CrCl 30 to 59 mL/min is a proactive prescribing requirement, not a reactive threshold to be applied only if renal function declines further — initiating at 137 mg and waiting for CrCl to fall below 30 mL/min risks accumulation and toxicity in the interim.

ANSWER: D

Rationale:

The EASE LID and EASE LID 3 trials are the pivotal randomized, placebo-controlled studies that established the evidence base for Gocovri's 2017 FDA approval for levodopa-induced dyskinesia. The primary efficacy finding in pooled analysis was a statistically significant reduction in UDysRS scores of approximately 41% from baseline versus approximately 14% with placebo — a placebo-subtracted difference of roughly 27% that translates to observable functional improvement of the kind this patient is already experiencing at four weeks. Critically, amantadine ER also reduced daily off-time as a secondary endpoint without worsening total on-time, meaning patients gained dyskinesia control without the motor trade-off that levodopa dose reduction would impose. An important caveat for this specific patient is that the trials used the full 137 mg dose; his renally adjusted ceiling of 68.5 mg is half the trial dose, and while benefit is still expected and already observed, the magnitude may be somewhat less than the trial average. Honest counseling should acknowledge this and set realistic expectations. Option D correctly summarizes the trial findings and introduces the dose-specific caveat relevant to this patient.

• Option A: Option A is incorrect; the trials reported mean group reductions in UDysRS scores, not complete elimination rates — the proportions described are fabricated and substantially overstate the drug's effect.
• Option B: Option B is incorrect; the primary endpoint was dyskinesia (UDysRS), not on-time extension; the four-hour on-time extension figure is a significant overstatement of the trial's secondary endpoint findings.
• Option C: Option C is incorrect; the EASE LID trials enrolled patients who were permitted to be on COMT inhibitors — the evidence base is not restricted to COMT inhibitor-naive patients, and this patient's entacapone does not preclude application of trial data.
• Option E: Option E is incorrect; UDysRS score reduction was the primary efficacy endpoint and did reach statistical significance in both pivotal trials — approval was based on this objective dyskinesia rating scale, not solely on patient-reported measures.

ANSWER: A

Rationale:

Livedo reticularis is a well-characterized and distinctive adverse effect of amantadine in both its immediate-release and extended-release formulations. It presents as a mottled, net-like purplish discoloration of the extremities caused by cutaneous vasospasm affecting the small dermal vessels. The clinical features in this patient — bilateral symmetric net-like purplish skin discoloration, warm feet, intact pulses, no edema, no pain — are exactly consistent with amantadine-related livedo reticularis and are incompatible with ischemic, thrombotic, or edematous causes. This adverse effect is benign, does not indicate systemic disease or vascular compromise, and resolves upon drug discontinuation. Patients should be informed proactively about this potential adverse effect at the time of prescribing; when it appears unexpectedly, reassurance and clear explanation are the appropriate response. Drug discontinuation is not required unless the patient finds the cosmetic appearance unacceptable. Given that this patient's dyskinesia is responding well to Gocovri, the benefit-risk balance favors continuation with reassurance. Option A correctly identifies the finding, provides appropriate reassurance, and preserves the therapeutic benefit.

• Option B: Option B is incorrect; livedo reticularis from amantadine is a benign vasospastic phenomenon with no ischemic mechanism — the warm feet and intact pulses directly exclude peripheral arterial insufficiency.
• Option C: Option C is incorrect; livedo reticularis occurs with both immediate-release and extended-release amantadine formulations — it is not caused by the extended-release polymer matrix but by the amantadine molecule itself, and rechallenge with immediate-release would be expected to reproduce the finding.
• Option D: Option D is incorrect; livedo reticularis is not edema and is not caused by sodium retention — the two conditions have entirely different appearances, mechanisms, and management approaches.
• Option E: Option E is incorrect; calciphylaxis is a serious vascular calcification syndrome associated with end-stage renal disease and secondary hyperparathyroidism — it presents with painful ischemic skin lesions, not painless reticular vasospastic discoloration, and is not caused by amantadine.

ANSWER: C

Rationale:

The threshold for Gocovri contraindication is clearly defined in the prescribing information: creatinine clearance below 30 mL/min or end-stage renal disease requires avoidance of the drug at any dose. This patient's CrCl of 27 mL/min has crossed this threshold due to progressive CKD, not an acute reversible event. At this level of renal function, amantadine clearance is sufficiently impaired that even the lowest available dose (68.5 mg) will produce accumulation to concentrations associated with CNS and other toxicity — hallucinations, myoclonus, confusion, and cardiac effects. No dose reduction can fully compensate for the degree of renal impairment; the prescribing information reflects a judgment that below CrCl 30 mL/min, the risk of accumulation-related toxicity outweighs any potential benefit at any dose. The correct action is discontinuation with counseling about the need for alternative dyskinesia management approaches — which may include levodopa dose adjustment, consideration of continuous levodopa infusion systems, or deep brain stimulation evaluation if the patient is an appropriate candidate. Option C correctly applies the renal contraindication.

• Option A: Option A is incorrect; the 30 mL/min threshold is a firm prescribing boundary in the approved labeling, not a conservative estimate subject to clinical override based on current tolerability — drug accumulation is progressive and toxicity may develop before it is clinically apparent.
• Option B: Option B is incorrect; deferring discontinuation for four weeks to confirm the CrCl reading introduces unacceptable accumulation risk when CrCl has declined from 42 to 27 mL/min in a patient with progressive CKD — this is not a transient measurement artefact but a clinically meaningful renal function change requiring immediate action.
• Option D: Option D is incorrect; a 34 mg every-other-day regimen does not exist in the approved amantadine ER prescribing information — no validated dosing schedule for CrCl below 30 mL/min exists, and improvised reduced-frequency regimens have not been studied for safety or efficacy at this renal function level.
• Option E: Option E is incorrect; the prescribing information for amantadine-containing products contraindicates use in ESRD and on dialysis because dialytic clearance of amantadine is insufficient to prevent accumulation between sessions — switching to immediate-release on dialysis days is not an approved or safe strategy at this level of renal impairment.

ANSWER: E

Rationale:

This case illustrates the progressive and insidious nature of anticholinergic toxicity in PD as underlying neurodegeneration advances. When trihexyphenidyl was initiated six years ago, the patient's cholinergic reserve was presumably sufficient to tolerate its muscarinic blocking effects without severe cognitive consequences. As PD has progressed, however, the disease has increasingly depleted cortical and hippocampal cholinergic neurons — the same neurons whose signaling underpins cognitive function — reducing the patient's cholinergic reserve to a level at which the dose of trihexyphenidyl that was previously tolerated is now producing overt cognitive impairment. The cognitive decline over eight months is pharmacologically accelerated PD dementia, not simply natural disease progression, because removing the anticholinergic contribution may allow partial cognitive recovery. Simultaneously, peripheral M3 receptor blockade on the detrusor muscle has produced urinary retention by reducing detrusor contractility — a well-established peripheral adverse effect of anticholinergics that is mechanistically distinct from dopaminergic bladder dysfunction. Both findings have a single root pharmacological cause: the anticholinergic drug in a patient whose reserve to tolerate it has been eroded by disease. Option E correctly identifies both the central and peripheral mechanisms of trihexyphenidyl toxicity in this advanced disease context.

• Option A: Option A is incorrect; while PD dementia is a real entity, the temporal relationship between progressive disease and the patient's declining cholinergic reserve makes trihexyphenidyl a clinically meaningful and removable contributor to her cognitive decline — attributing everything to disease progression without addressing the pharmacological contributor fails the patient.
• Option B: Option B is incorrect; the patient's dopaminergic therapy is unchanged and there is no basis for attributing her cognitive decline to levodopa toxicity; urinary retention from anticholinergic detrusor suppression is a more parsimonious explanation than pelvic floor motor dysfunction.
• Option C: Option C is incorrect; vasovagal autonomic instability does not produce progressive cognitive decline or the specific pattern of urinary retention requiring catheterization; trihexyphenidyl's anticholinergic mechanism is directly linked to both findings.
• Option D: Option D is incorrect; urinary retention in this patient is caused by anticholinergic detrusor suppression, not detrusor overactivity — muscarinic blockade reduces detrusor contractility, which in a patient who may also have some outflow resistance produces urinary retention; this is the pharmacologically correct mechanism.

ANSWER: C

Rationale:

This question tests the integration of two clinical principles: the correct trihexyphenidyl deprescribing approach and the recognition that adding oxybutynin — another anticholinergic agent — to manage symptoms caused by anticholinergic burden is pharmacologically self-defeating. The trihexyphenidyl taper must be gradual: a 25 to 50 percent dose reduction every two to four weeks avoids cholinergic rebound withdrawal (nausea, sweating, anxiety) and allows monitoring for tremor worsening during the taper. Abrupt discontinuation after six years at any dose is not appropriate even in the context of clinical urgency. The oxybutynin prescription must be actively intercepted. Oxybutynin is a non-selective muscarinic antagonist with significant CNS penetrance that carries substantial anticholinergic cognitive burden — it would add to, not replace, the central anticholinergic load that is causing this patient's cognitive decline. Furthermore, the urinary symptoms in this patient are likely caused by anticholinergic detrusor suppression from trihexyphenidyl, not by overactive bladder in the usual sense; removing trihexyphenidyl may resolve the urinary retention without any additional bladder drug. If bladder symptoms persist after the anticholinergic taper, mirabegron — a beta-3 adrenergic agonist that relaxes the detrusor through a non-anticholinergic mechanism — is the appropriate non-anticholinergic substitute. Option C correctly prescribes the taper approach and actively declines the oxybutynin in favor of a non-anticholinergic alternative.

• Option A: Option A is incorrect on two counts: abrupt trihexyphenidyl discontinuation risks withdrawal syndrome and tremor rebound, and adding oxybutynin simultaneously replaces one anticholinergic with another while compounding the central burden.
• Option B: Option B is incorrect; oxybutynin has clinically significant CNS penetrance and anticholinergic cognitive burden that is not eliminated by keeping the dose below 5 mg daily — no dose of oxybutynin is "safe" for CNS purposes in a patient with PD and cognitive impairment from anticholinergic toxicity.
• Option D: Option D is incorrect; the cognitive adverse effects of oxybutynin are pharmacodynamic — they result from muscarinic receptor blockade at any point in time and do not depend on concurrent use of other anticholinergic drugs; adding it after trihexyphenidyl is discontinued would still impose central anticholinergic burden.
• Option E: Option E is incorrect; donepezil is not an appropriate immediate intervention before the anticholinergic burden is removed — starting a cholinesterase inhibitor while the source of anticholinergic burden is still present or being tapered misorders the pharmacological priorities.

ANSWER: A

Rationale:

Tremor worsening during anticholinergic taper is an anticipated and manageable complication, not a reason to abandon discontinuation when the clinical imperative — in this case, significant cognitive impairment — is compelling. The established management strategy for tremor rebound during anticholinergic taper is to add a non-anticholinergic tremor-bridging agent to provide alternative tremor control while the taper continues to completion. Propranolol, a non-selective beta-adrenergic blocker with established tremor-suppressing activity, and clonazepam, a long-acting benzodiazepine with tremor-modulating effects, are the most commonly used bridging options. The cognitive improvement already observed during the taper provides strong evidence that the cognitive decline was at least partially pharmacological and pharmacologically reversible — this reinforces the clinical imperative to complete discontinuation rather than halt at a reduced dose. After full discontinuation, the patient's tremor can be reassessed in the context of her fully optimized dopaminergic regimen, and further tremor-specific therapy can be planned based on the residual tremor burden. Option A correctly applies the bridging strategy and maintains the priority of completing discontinuation given the cognitive benefit.

• Option B: Option B is incorrect; halting the taper at 2 mg/day and maintaining indefinitely leaves the patient on a drug that is contraindicated in her cognitive state and sacrifices the cognitive improvement trajectory for the sake of tremor management that can be achieved through non-anticholinergic means.
• Option C: Option C is incorrect; reversing a taper because of tremor worsening — when the tremor is an expected consequence of removing a drug that was suppressing it — reintroduces the pharmacological cause of her cognitive impairment; the cognitive improvement during the taper argues strongly against the premise that it was coincidental.
• Option D: Option D is incorrect; doubling levodopa does not reliably suppress parkinsonian resting tremor — levodopa is more effective for bradykinesia and rigidity than for tremor, and dose doubling carries its own risks including dyskinesia and neuropsychiatric adverse effects.
• Option E: Option E is incorrect; tremor worsening during anticholinergic taper does not constitute a surgical emergency requiring immediate DBS referral — the tremor is an expected pharmacological consequence of removing the drug, not evidence of a refractory tremor disorder that is beyond pharmacological management.

ANSWER: D

Rationale:

This question requires integrating the reversibility of pharmacological cognitive impairment with the natural history of PD-related cognitive decline to make a reasoned prescribing decision about cholinesterase inhibitor therapy. The cognitive recovery from MMSE 19 to 24 following trihexyphenidyl discontinuation provides strong evidence that the anticholinergic burden was a pharmacologically meaningful contributor to cognitive decline — this recovery of 5 points is clinically substantial. However, the residual gap of 3 points below her two-year-ago baseline raises the question of whether this reflects: ongoing pharmacological effect still resolving (anticholinergic cognitive effects can take several months to fully clear), underlying PD-related cholinergic neurodegeneration that was unmasked by removing the reversible component, or both. Donepezil, a reversible acetylcholinesterase inhibitor approved for PD dementia, is a reasonable therapeutic consideration at this stage — now that the anticholinergic burden that would have pharmacologically opposed its mechanism has been removed. However, the decision to commit to long-term cholinesterase inhibitor therapy is best made after observing the trajectory of cognitive recovery over an additional two to three months. If MMSE continues to improve spontaneously, pharmacological augmentation may prove unnecessary. If it plateaus well below her prior baseline, donepezil becomes the appropriate next step. Option D correctly frames this as a time-contingent decision requiring further observation before commitment.

• Option A: Option A is incorrect; there is no established contraindication to cholinesterase inhibitors in patients who have previously experienced anticholinergic-induced cognitive impairment — the prior anticholinergic exposure does not create permanent sensitivity to cholinesterase inhibition.
• Option B: Option B is incorrect; initiating donepezil at the maximum dose immediately without allowing further spontaneous recovery is premature — the full reversal of anticholinergic cognitive effects may not be complete at three months, and beginning at maximum dose unnecessarily forecloses titration-based assessment of benefit.
• Option C: Option C is incorrect; cognitive recovery in the context of anticholinergic removal is not universally complete — PD causes cholinergic neurodegeneration that contributes to cognitive decline independently of drug exposure, and a patient who recovers partially but not fully may have both pharmacological and disease-related components to address.
• Option E: Option E is incorrect; an MMSE of 24/30 with 3-point deficit below a prior baseline does not constitute a formal diagnosis of PD dementia requiring immediate treatment — PD dementia is a clinical diagnosis requiring cognitive impairment in multiple domains that significantly interferes with daily function, not a threshold score on a single screening instrument.

ANSWER: C

Rationale:

This case illustrates the clinical rationale for istradefylline's position in the treatment algorithm: it fills a mechanistically distinct niche when dopaminergic adjunct options have been optimized. Entacapone reduces peripheral COMT-mediated levodopa catabolism, extending levodopa's plasma half-life and smoothing its concentration-time profile. Rasagiline inhibits intraneuronal MAO-B, reducing dopamine catabolism within surviving nigrostriatal terminals and extending dopaminergic effect duration. Both mechanisms operate within the dopaminergic pharmacological space. When these are optimized and off-time persists, further dopaminergic escalation may be constrained by tolerability — dyskinesia, hallucinations, orthostatic hypotension, and impulse control disorders are dose-limiting adverse effects that accumulate with each additional dopaminergic agent. Istradefylline's adenosine A2A receptor antagonism on striatopallidal neurons reduces indirect pathway overactivity through a glutamatergic-adenosinergic circuit that is mechanistically independent of dopamine receptors, synthesis, and metabolism. It can therefore provide additional off-time reduction without further compounding the dopaminergic adverse effect profile. Option C correctly identifies this mechanistic independence as the clinical rationale.

• Option A: Option A is incorrect; istradefylline does not inhibit COMT at any site — COMT inhibition is the mechanism of entacapone and tolcapone; istradefylline has no pharmacological relationship to the COMT enzyme.
• Option B: Option B is incorrect; the combination of rasagiline and istradefylline does not create a pharmacodynamic interaction producing excessive dyskinesia risk — the clinical trial program for istradefylline enrolled patients on MAO-B inhibitors without identifying this as a problematic combination.
• Option D: Option D is incorrect; istradefylline is not a prodrug requiring MAO-B activation — it is pharmacologically active as administered; co-administration with rasagiline is not contraindicated on this basis.
• Option E: Option E is incorrect; istradefylline does not stimulate dopamine release from nigrostriatal terminals — it acts postsynaptically on striatopallidal neurons through adenosine receptor blockade, entirely distinct from presynaptic dopamine release mechanisms.

ANSWER: B

Rationale:

Istradefylline is metabolized primarily by CYP3A4. Fluconazole is a well-characterized moderate CYP3A4 inhibitor — less potent than ketoconazole or itraconazole but clinically significant at the 200 mg daily dose used here. By reducing CYP3A4 metabolic activity, fluconazole decreases istradefylline clearance and raises its steady-state plasma concentrations. At the 40 mg dose — the maximum approved dose — istradefylline plasma concentrations were already at the upper therapeutic range; moderate CYP3A4 inhibition by fluconazole has pushed concentrations above the adverse effect threshold, producing hallucinations through enhanced limbic circuit effects and worsening dyskinesia through the pharmacodynamic consequence of greater indirect pathway disinhibition amplifying net motor drive. The appropriate response is to reduce istradefylline to 20 mg once daily, the lower approved dose, which will lower the steady-state concentration even in the presence of CYP3A4 inhibition, and to monitor for resolution of adverse effects as concentrations normalize over the following weeks. The fluconazole course will end at six weeks, at which point istradefylline clearance will return to baseline and the dose may be reconsidered. Option B correctly identifies the CYP3A4 inhibition mechanism, the concentration-dependent adverse effect, and the appropriate dose management.

• Option A: Option A is incorrect; fluconazole does not inhibit MAO-B — it inhibits human CYP51 and CYP3A4; the adverse effects are attributable to istradefylline accumulation, not rasagiline toxicity.
• Option C: Option C is incorrect; while azole antifungals do target fungal CYP51, fluconazole also has well-documented inhibitory activity against human CYP3A4 at therapeutic doses — this is the basis of multiple clinically significant drug interactions with azoles.
• Option D: Option D is incorrect; there is no pharmacodynamic interaction between fluconazole's ergosterol synthesis inhibition and istradefylline's A2A receptor mechanism — this is a fabricated interaction; the mechanism is pharmacokinetic CYP3A4 inhibition, not pharmacodynamic.
• Option E: Option E is incorrect; fluconazole inhibits, not induces, CYP3A4 — CYP3A4 induction is the mechanism of rifampin, carbamazepine, and phenytoin; the adverse effects here result from elevated, not reduced, istradefylline concentrations.

ANSWER: E

Rationale:

This question tests understanding of the time course of recovery from CYP3A4 inhibition and the distinction between pharmacokinetic drug interactions and inherent drug intolerance. Fluconazole's inhibition of CYP3A4 is reversible — it is a non-mechanism-based (competitive or mixed) inhibitor whose inhibitory effect is eliminated as the drug is cleared from the body. Fluconazole has a half-life of approximately 30 hours; after discontinuation, its plasma concentrations fall substantially within two to three days and CYP3A4 activity recovers over approximately one to two weeks as the drug clears and enzyme activity normalizes. Once CYP3A4 activity is restored, istradefylline clearance returns to its pre-fluconazole baseline and the 40 mg dose will produce concentrations equivalent to those the patient was tolerating before fluconazole was added — without the drug interaction-related adverse effects. The hallucinations and dyskinesia during the fluconazole course were a predictable pharmacokinetic drug interaction, not evidence that 40 mg of istradefylline is inherently intolerable for this patient. A reasonable approach is to wait approximately one to two weeks after fluconazole discontinuation — allowing for full CYP3A4 recovery — before uptitrating back to 40 mg, and to monitor for any recurrence of adverse effects. Option E correctly identifies the reversible inhibition mechanism, the appropriate waiting period, and the clinical distinction between pharmacokinetic interaction and inherent intolerance.

• Option A: Option A is incorrect; the adverse effects at 40 mg occurred specifically in the context of CYP3A4 inhibition by fluconazole — they do not indicate that 40 mg is the patient's inherent maximum tolerated dose, since he had tolerated it without incident before fluconazole was added.
• Option B: Option B is incorrect; while fluconazole's competitive inhibition does begin to resolve as the drug clears, immediate same-day uptitration on the day of discontinuation does not allow adequate time for CYP3A4 activity to normalize — a brief waiting period of one to two weeks is more appropriate.
• Option C: Option C is incorrect; fluconazole does not produce irreversible (mechanism-based) CYP3A4 inhibition of the type that requires new enzyme protein synthesis over months — it is a reversible inhibitor whose effect resolves as the drug clears, typically over days to a few weeks.
• Option D: Option D is incorrect; therapeutic drug monitoring of istradefylline plasma levels is not a standard clinical requirement in the prescribing information — approved dose management is based on clinical assessment of efficacy and adverse effects, not mandatory pharmacokinetic confirmation.

ANSWER: A

Rationale:

This question integrates the pharmacokinetic smoking interaction with the retrospective understanding of why this patient is doing well on the maximum 40 mg istradefylline dose. Tobacco smoke contains polycyclic aromatic hydrocarbons (PAHs) that activate the aryl hydrocarbon receptor (AhR) transcription factor, inducing the expression of multiple CYP enzymes including both CYP1A2 and CYP3A4. Because istradefylline is metabolized primarily by CYP3A4, tobacco smoking substantially increases istradefylline clearance and reduces steady-state plasma concentrations compared to what a non-smoker would achieve at the same dose. The prescribing information for istradefylline specifically acknowledges this interaction and notes that smokers may require the 40 mg dose to achieve plasma concentrations equivalent to those in non-smokers on 20 mg. This patient's need for 40 mg — which was decided empirically based on off-time response — is thus pharmacokinetically coherent: his CYP3A4 induction from smoking has been requiring the higher dose to compensate for accelerated drug clearance. Understanding this retrospectively confirms that his current 40 mg dose is appropriately matched to his pharmacokinetic phenotype as a smoker, even though it was not initially prescribed with that rationale in mind. Option A correctly identifies the CYP3A4 induction mechanism of tobacco smoke through PAH-mediated AhR activation and draws the appropriate clinical conclusion.

• Option B: Option B is incorrect; tobacco smoke induces both CYP1A2 and CYP3A4 through the same AhR mechanism — characterizing the induction as selective for CYP1A2 ignores the well-documented CYP3A4 component that is directly relevant to istradefylline pharmacokinetics.
• Option C: Option C is incorrect; tobacco smoking induces, not inhibits, CYP3A4 — nicotine-mediated competitive enzyme occupancy is not the mechanism; the induction increases clearance and reduces concentrations rather than the reverse.
• Option D: Option D is incorrect; the prior fluconazole exposure occurred weeks ago and fluconazole's reversible CYP3A4 inhibition has fully resolved — there is no ongoing cancellation of effects between historical fluconazole inhibition and current smoking induction.
• Option E: Option E is incorrect; the maximum approved dose of istradefylline is 40 mg once daily — a 60 mg dose does not exist in the approved prescribing information and the clinical pharmacology data do not support exceeding the approved maximum in smokers.

ANSWER: D

Rationale:

Abrupt discontinuation of multiple antiparkinsonian agents in a hospitalized PD patient is a well-recognized perioperative hazard that can produce an NMS-like syndrome — sometimes called parkinsonism-hyperpyrexia syndrome — which is mechanistically distinct from true NMS but clinically similar in its severity. In this patient, two separate contributions to the deterioration occurred simultaneously: abrupt anticholinergic withdrawal from trihexyphenidyl produced cholinergic rebound that acutely destabilized the dopaminergic-cholinergic balance in the striatum, and discontinuation of amantadine ER removed both its NMDA-antagonist antidyskinetic contribution and its modest dopaminergic motor-stabilizing effect. The combined result is severe acute motor deterioration with autonomic instability, hyperthermia, and muscle breakdown (elevated CK from rigidity and immobility). This is not true NMS — which requires exposure to a dopamine-blocking agent — and treating it as NMS with dantrolene while withholding dopaminergic agents would be harmful. The correct response is urgent reinstatement of all PD medications through the nasogastric tube or as crushed formulations if necessary. Levodopa/carbidopa takes priority as the primary dopaminergic agent; amantadine ER reinstatement follows given its dual contribution; trihexyphenidyl should be restarted with a plan for eventual gradual taper once the acute crisis resolves. True NMS is excluded by the absence of a dopamine-blocking agent and by the history of abrupt medication withdrawal. Option D correctly identifies the withdrawal-precipitated syndrome and the reinstatement priority sequence.

• Option A: Option A is incorrect; spinal anesthetic agents do not block dopamine receptors, and withholding dopaminergic medications would worsen rather than treat the withdrawal-precipitated syndrome.
• Option B: Option B is incorrect; serotonin syndrome requires neuromuscular excitability signs — clonus, hyperreflexia, myoclonus — and a precipitating serotonergic agent interaction; the clinical picture here does not match, and spinal anesthetics with opioids do not cause serotonin syndrome through this mechanism.
• Option C: Option C is incorrect; levodopa toxicity produces dyskinesia and hallucinations, not severe rigidity, hyperthermia, and elevated CK; withholding levodopa in a patient who is deteriorating from insufficient dopaminergic support is the opposite of the correct management.
• Option E: Option E is incorrect; malignant hyperthermia is triggered by volatile inhalational anesthetics and succinylcholine — this patient had spinal anesthesia, not general anesthesia with inhalational agents; malignant hyperthermia characteristically presents intraoperatively or immediately postoperatively, not 48 hours later.

ANSWER: A

Rationale:

Gocovri (amantadine ER 137 mg) is formulated as an extended-release capsule containing drug-loaded beads or granules within a controlled-release matrix designed to produce a broad plasma concentration peak during the morning hours after bedtime dosing. Crushing the capsule would physically destroy this matrix, converting the extended-release formulation to an immediate-release delivery with a rapid peak concentration — eliminating the pharmacokinetic design rationale for bedtime dosing and potentially producing amantadine concentrations higher than intended for a shorter duration, which could increase CNS adverse effects such as hallucinations and dizziness. The prescribing information for Gocovri specifies that the capsule should not be crushed or chewed but may be opened and the intact contents (beads or granules) sprinkled onto soft food such as applesauce for patients who have difficulty swallowing capsules — or delivered via nasogastric tube without crushing the individual beads. This preserves the extended-release matrix and maintains the intended pharmacokinetic profile. Option A correctly identifies the extended-release matrix protection rationale and the correct administration alternative.

• Option B: Option B is incorrect; Gocovri can be administered via nasogastric tube using the sprinkle method — sodium-drug-irrigant precipitation is a fabricated concern not described in the prescribing information.
• Option C: Option C is incorrect; the extended-release matrix of Gocovri is designed to function across the range of gastrointestinal pH encountered physiologically, including postoperative gastric pH — pH-dependent inactivation of the matrix to produce overdose is not a pharmacologically accurate mechanism.
• Option D: Option D is incorrect; while timing the administration to approximate bedtime is clinically preferable to maintain the morning-peak pharmacokinetic profile, the bedtime requirement is not an absolute contraindication to nasogastric delivery — the clinical priority is reinstating the drug at all, and the timing can be optimized as the patient's status evolves.
• Option E: Option E is incorrect; amantadine is not a prodrug requiring oral mucosal absorption — it is an active drug absorbed through the gastrointestinal epithelium; nasogastric delivery does not bypass its mechanism of absorption.

ANSWER: C

Rationale:

The perioperative reinstatement of trihexyphenidyl was the correct acute management — restoring stability after abrupt withdrawal was the clinical priority and outweighed the chronic contraindication considerations in the acute crisis. However, the same clinical reasoning that made reinstatement necessary in the acute setting does not justify continued indefinite prescription of a drug that now has two documented contraindications in this patient: age 73 (a relative but strong contraindication in PD guidelines) and mild cognitive impairment (an independent contraindication to anticholinergic use in PD). The correct discharge plan acknowledges that the acute crisis has been resolved, that the patient must go home on the reinstated dose to avoid another abrupt discontinuation event, and that outpatient neurology should coordinate a scheduled gradual taper — reducing by 25 to 50 percent every two to four weeks — over the weeks following discharge, with the goal of complete discontinuation. This converts the emergency reinstatement into a planned and supervised discontinuation process. Option C correctly identifies the two contraindications, acknowledges the rational basis for acute reinstatement, and prescribes the appropriate discharge plan.

• Option A: Option A is incorrect; deferring any action for three months ignores two active contraindications and allows continued anticholinergic exposure to a patient with MCI without a plan for discontinuation.
• Option B: Option B is incorrect; increasing the dose of a contraindicated drug to prevent future withdrawal events is pharmacologically perverse — the correct prevention strategy is a planned supervised taper to discontinuation, not dose escalation.
• Option D: Option D is incorrect; surviving the withdrawal episode does not eliminate the contraindications — the episode actually reinforces the need to discontinue the drug through a planned taper rather than allowing future abrupt withdrawal events that could be even more severe.
• Option E: Option E is incorrect; switching to benztropine does not resolve the contraindications — benztropine is also a muscarinic antagonist with the same cognitive and peripheral adverse effect profile as trihexyphenidyl, and its once-daily dosing does not provide a meaningful pharmacokinetic buffer against the consequences of abrupt discontinuation in future hospitalizations.

ANSWER: E

Rationale:

The institutional lesson from this case is comprehensive and directly actionable for perioperative protocol design. The fundamental error that precipitated this patient's crisis was classifying trihexyphenidyl and amantadine ER as "non-essential" medications subject to routine perioperative holds — a classification that is dangerously incorrect for antiparkinson agents. The core perioperative principle for PD patients is that their medications must be continued without interruption whenever possible, and when NPO status is unavoidable, alternative delivery routes must be planned proactively rather than discovered reactively after a crisis has developed. This requires preoperative neurology consultation for elective procedures — ideally weeks before the operative date — to: review the full regimen and identify drugs that cannot be safely withheld, plan alternative delivery including crushed levodopa/carbidopa via nasogastric tube and Gocovri bead-sprinkle delivery, communicate the reinstatement priority sequence to the surgical and anesthesia teams, and educate the postoperative nursing team to recognize early signs of medication withdrawal and to differentiate parkinsonism-hyperpyrexia syndrome from true NMS. Option E correctly identifies preoperative neurology consultation as the structural solution and articulates the key educational content the consult should convey.

• Option A: Option A is incorrect; holding all antiparkinson medications perioperatively is exactly the harmful practice this case demonstrates — the risk of parkinsonism-hyperpyrexia syndrome from abrupt discontinuation is not an "acceptable" trade-off and drug interactions with anesthetics are generally not a primary concern for the agents in this patient's regimen.
• Option B: Option B is incorrect; peripherally acting dopaminergic agents that do not cross the BBB cannot replicate the CNS therapeutic effects of levodopa or amantadine ER — no such substitution strategy exists in clinical practice.
• Option C: Option C is incorrect; this reverses the clinical priority — dopaminergic agents including levodopa are the most critical antiparkinson medications to continue perioperatively, and anticholinergics, while also important to taper rather than abruptly stop, are not the sole priority.
• Option D: Option D is incorrect as stated because, while it identifies the error of the "non-essential" classification, it addresses the problem only reactively and fails to specify preoperative neurology consultation as the structural prevention mechanism that Option E correctly identifies as the institutional solution.

ANSWER: B

Rationale:

DIP caused by metoclopramide shares the same fundamental pathophysiology as anticholinergic efficacy in idiopathic PD: the relative cholinergic excess that results from inadequate dopaminergic suppression of striatal cholinergic interneurons. In idiopathic PD, this occurs because of nigrostriatal degeneration reducing dopamine availability. In DIP from metoclopramide, dopaminergic neurons are intact but functionally blocked — the D2 receptor antagonism by metoclopramide at the level of the striatal cholinergic interneurons prevents dopamine from exerting its normal inhibitory effect, producing the same net result of cholinergic interneuron overactivity. Muscarinic receptor blockade by trihexyphenidyl or benztropine can reduce the consequences of this relative cholinergic excess, providing symptomatic relief while metoclopramide continues. This is a pharmacologically rational short-term bridge. However, the more important clinical priority is to address the underlying cause: DIP is mechanistically reversible by removing or substituting the offending agent. Domperidone (if available) and erythromycin are prokinetic alternatives that do not cross the blood-brain barrier in clinically significant amounts and therefore do not cause DIP — substituting one of these for metoclopramide would allow DIP to resolve without requiring ongoing anticholinergic therapy. Option B correctly identifies the anticholinergic mechanism as rational for DIP and frames the superior long-term strategy.

• Option A: Option A is incorrect; anticholinergic therapy is pharmacologically appropriate for DIP and can provide meaningful symptom relief while the clinical situation is reassessed; the premise that D2 blockade cannot be overcome at all by muscarinic blockade is incorrect — the two mechanisms act at different receptor targets on overlapping circuits.
• Option C: Option C is incorrect; while young cognitively intact patients have better tolerability for anticholinergics than elderly patients with PD, aggressive dose escalation without stepwise titration is not appropriate at any age — adverse effects including dry mouth, urinary retention, and tachycardia remain dose-dependent.
• Option D: Option D is incorrect; DIP is not caused by dopamine receptor downregulation requiring agonist restoration — it is caused by active competitive D2 blockade from metoclopramide; adding a dopamine agonist would compete with metoclopramide at the same D2 receptor and might provide some benefit but is not the mechanistically preferred approach and introduces mesolimbic adverse effect risk.
• Option E: Option E is incorrect; there is no recommendation for 12-month observation before treating functionally significant DIP — symptom management and cause elimination should be addressed promptly, not deferred.

ANSWER: E

Rationale:

The approach to anticholinergic discontinuation in recovering DIP shares the general withdrawal-management principle with idiopathic PD but differs in clinical goal and pace. The shared principle is that abrupt discontinuation after any period of anticholinergic use risks cholinergic rebound withdrawal symptoms — nausea, sweating, anxiety — and should be avoided; a gradual taper with 25 to 50 percent dose reductions every two to four weeks is appropriate in both settings. The critical difference is in the final destination of the taper: in idiopathic PD, nigrostriatal degeneration is permanent and the relative cholinergic excess that anticholinergics correct does not resolve with drug removal — tremor returns to its pre-treatment severity and complete discontinuation carries a permanent motor cost. In this patient with DIP that has resolved following metoclopramide discontinuation, the underlying mechanism — D2 receptor blockade producing relative cholinergic excess — has been eliminated. The striatal dopaminergic-cholinergic balance has been restored by her intact nigrostriatal system, and benztropine is no longer correcting a persistent deficit. Complete discontinuation is therefore both achievable and appropriate, and the taper can proceed more quickly than in idiopathic PD because the risk of clinically significant tremor rebound at the end of the taper is low. Option E correctly preserves the shared withdrawal-avoidance principle and articulates the disease-specific difference in goal and pace.

• Option A: Option A is incorrect; 12 to 18 months is an inappropriately prolonged taper for DIP with documented motor recovery — this pace would be appropriate only if the indication for the anticholinergic were expected to persist, which it is not.
• Option B: Option B is incorrect; abrupt discontinuation is inappropriate even in recovering DIP — while the tremor rebound risk is lower than in idiopathic PD, cholinergic withdrawal symptoms (nausea, sweating, anxiety) remain a risk from abrupt cessation and a taper is still the correct approach.
• Option C: Option C is incorrect; D2 receptor supersensitivity from prior metoclopramide exposure does not create a permanent requirement for anticholinergic maintenance — receptor sensitivity normalizes over weeks to months after the blocking agent is removed, and there is no pharmacological basis for indefinite low-dose maintenance in a patient with resolved DIP.
• Option D: Option D is incorrect; domperidone does not cause central DIP because its quaternary ammonium structure substantially limits blood-brain barrier penetration — its peripheral D2 blockade does not require anticholinergic coverage to prevent central parkinsonian effects.

ANSWER: D

Rationale:

This question integrates the clinical profile of istradefylline with the patient's history to determine whether the prior DIP episode affects current prescribing. Istradefylline's approved indication is as an adjunct to levodopa/carbidopa in adults with PD experiencing off episodes — this patient meets the indication. The prior DIP episode, which has been resolved for over two years and from which the patient's DIP-related motor symptoms fully recovered, does not create any pharmacological or regulatory contraindication to istradefylline use. D2 receptor supersensitivity from prior metoclopramide exposure is a transient phenomenon that normalizes over weeks to months after drug removal — it does not persist for years and does not represent a pharmacological interaction risk with istradefylline's A2A mechanism. The patient's intact cognition and normal hepatic function remove the two most common prescribing constraints: MCI (which requires heightened monitoring) and hepatic impairment (which caps the dose at 20 mg). The prescribing conversation should include all elements of informed consent for istradefylline: its Schedule V classification, the impulse control disorder warning, the realistic expectation of approximately 0.9 hours per day off-time reduction based on the trial program, and the CYP3A4 drug interaction profile. Option D correctly identifies istradefylline as appropriate, confirms that the DIP history is not a contraindication, and outlines the prescribing conversation.

• Option A: Option A is incorrect; D2 receptor supersensitivity from metoclopramide does not persist for 18 months after drug removal and does not create a contraindication to istradefylline — the mechanism described is pharmacologically fabricated as a chronic persistent effect.
• Option B: Option B is incorrect; there is no age threshold in istradefylline's prescribing information restricting use to patients over age 65 — the indication applies to adults with PD experiencing off episodes regardless of age, and the ICD warning is relevant across all age groups but does not make the drug off-limits to younger adults.
• Option C: Option C is incorrect; the istradefylline clinical trial program enrolled patients with a range of PD onset ages, and characterizing the evidence as exclusively from patients over 60 with extrapolation to younger patients misrepresents the trial population.
• Option E: Option E is incorrect; the FDA-approved indication for istradefylline does not specify a minimum daily off-time threshold of three hours — the indication applies to patients "experiencing off episodes" without a numeric minimum, and two hours of daily off-time is a clinically meaningful burden that qualifies.

ANSWER: C

Rationale:

This question returns to the fundamental mechanism discrimination that opened Module 6 at the CC level — what is the right agent for what clinical problem — but at the T4 level of clinical complexity, incorporating occupational stakes, full renal function permitting the target dose, and the temptation to use anticholinergics in a young cognitively intact patient who fits the demographic profile for that drug class. The dominant clinical problem is dyskinesia limiting surgical work — functionally significant levodopa-induced dyskinesia for which Gocovri has a specific FDA indication based on the EASE LID trial program demonstrating in pooled analysis an approximately 41% reduction in UDysRS scores from baseline versus approximately 14% with placebo (a placebo-subtracted difference of roughly 27%). Gocovri's NMDA receptor antagonism operates independently of the dopaminergic and cholinergic systems; it is the right mechanism for the right problem. Her CrCl of 94 mL/min permits the full 137 mg target dose with standard one-week titration at 68.5 mg. Trihexyphenidyl is a muscarinic M1 antagonist with no established antidyskinetic mechanism — its clinical role is tremor suppression through correction of cholinergic excess, not dyskinesia reduction through glutamatergic modulation. The fact that this patient is young and cognitively intact makes her a suitable candidate for anticholinergics on demographic grounds, but suitability does not create an indication. Tremor is not identified as a dominant symptom, and adding trihexyphenidyl to address a non-dominant symptom with a drug that cannot address the dominant problem (dyskinesia) is pharmacologically incorrect. Option C correctly applies mechanism-to-indication matching.

• Option A: Option A is incorrect; trihexyphenidyl has no established antidyskinetic mechanism — muscarinic M1 blockade does not attenuate the glutamatergic NMDA-mediated component of levodopa-induced dyskinesia, and the claim of M1 selectivity for dyskinesia-generating corticostriatal circuits is pharmacologically inaccurate.
• Option B: Option B is incorrect; adding both agents simultaneously without establishing which addresses the primary problem is an irrational polypharmacy approach that introduces unnecessary adverse effect burden before the most specific agent has been given an adequate trial.
• Option D: Option D is incorrect; Gocovri does not worsen dyskinesia through "excessive NMDA blockade" in young patients — this mechanism is fabricated; NMDA antagonism at amantadine's clinical doses reduces dyskinesia by attenuating pathological glutamatergic drive.
• Option E: Option E is incorrect; DBS evaluation may eventually be appropriate in young-onset PD, but pharmacological management with Gocovri should be pursued before surgical intervention; characterizing all pharmacological dyskinesia agents as producing unacceptable occupational neuropsychiatric adverse effects in surgeons is an overstated and incorrect generalization.

ANSWER: A

Rationale:

This case presents the maximum complexity version of the neuropsychiatric polypharmacy challenge: three agents, each with overlapping adverse effect profiles across three symptom domains, in a patient whose cognitive impairment amplifies vulnerability to all of them. Pramipexole's D3 receptor agonism in the mesolimbic reward pathway is the most well-established pharmacological driver of impulse control disorders in PD — gambling behavior is among the most common ICDs reported with dopamine agonists and is the finding most pharmacologically attributable to pramipexole in this case. However, both amantadine ER and istradefylline also carry ICD warnings independently. Amantadine ER causes hallucinations and cognitive adverse effects through its combined NMDA antagonist and dopaminergic mechanisms; its bedtime dosing produces peak plasma concentrations during the overnight and early morning hours, making nocturnal confusion and evening hallucinations a temporally plausible pattern. Istradefylline carries a warning for hallucinations and impulse control disorders in its prescribing information and is classified as Schedule V. The presence of mild cognitive impairment in this patient removes any baseline buffer against neuropsychiatric adverse effects from any of the three agents — each drug is operating on a brain with reduced neuropsychiatric reserve. The only correct initial framework is to recognize the three-way overlap and commit to systematic de-escalation, one agent at a time, to isolate contributions. Option A correctly maps each agent to its neuropsychiatric risk profile and frames the three-way overlap problem.

• Option B: Option B is incorrect; attributing all three symptoms exclusively to Gocovri ignores the well-established ICD risk of pramipexole and the ICD and hallucination risk of istradefylline — a single-agent attribution in a three-drug overlap scenario without evidence is pharmacologically unjustified.
• Option C: Option C is incorrect; both hallucinations and nocturnal confusion can be pharmacologically caused by amantadine ER and istradefylline — attributing them exclusively to PD dementia before performing medication de-escalation does not meet the standard of clinical pharmacological reasoning.
• Option D: Option D is incorrect; Schedule V classification reflects low-level dependence potential, not high abuse potential in the recreational sense; furthermore, pramipexole is strongly associated with ICDs through its D3 mechanism, and amantadine ER also carries hallucination risk — istradefylline cannot be exclusively implicated for all three symptoms.
• Option E: Option E is incorrect; waiting for formal neuropsychological testing before adjusting any medication is clinically inappropriate when the patient is experiencing active gambling losses and hallucinations — medication de-escalation and neuropsychological evaluation should proceed in parallel, not in sequence.

ANSWER: C

Rationale:

Effective de-escalation in a three-agent polypharmacy neuropsychiatric presentation requires prioritizing both the most urgent symptom and the most pharmacologically attributable agent for that symptom, while managing the de-escalation pace to allow assessment of each change. The gambling behavior is the most urgent symptom — it is causing active, quantifiable financial harm that will worsen with each day of continued pramipexole exposure. Dopamine agonist-related impulse control disorders are among the most reproducibly established adverse drug effects in PD pharmacology, with D3 receptor agonism in the mesolimbic reward pathway as the mechanism; pramipexole reduction addresses the most pharmacologically attributable symptom with the most functional urgency. Simultaneously reducing Gocovri from 137 mg to 68.5 mg addresses the hallucination and nocturnal confusion contribution from the amantadine ER compartment — this is a dose reduction rather than discontinuation, preserving some dyskinesia control while reducing the neuropsychiatric exposure. Istradefylline is maintained temporarily because: its off-time contribution (1.5 hours daily) would be difficult to replace rapidly, its ICD and hallucination risks are lower than pramipexole's mesolimbic D3 mechanism for ICD, and maintaining one agent provides a stable pharmacological anchor during the de-escalation process. Reassessment in two to four weeks allows the team to determine whether the pramipexole reduction resolved the ICD and whether the Gocovri dose reduction reduced the hallucinations, before deciding whether further adjustments are needed. Option C correctly prioritizes urgent harm prevention (ICD from pramipexole), simultaneous but proportionate dose reduction of the hallucination contributor (Gocovri), and temporary maintenance of the off-time agent (istradefylline).

• Option A: Option A is incorrect; targeting Gocovri first over pramipexole fails to prioritize the most urgent and most pharmacologically attributable symptom — the active financial harm from ICD is more urgent than hallucinations, and pramipexole's D3 mechanism is more strongly established as the ICD driver.
• Option B: Option B is incorrect; Schedule V classification of istradefylline reflects low-level dependence potential, not the highest behavioral risk among the three agents — pramipexole's D3 mesolimbic ICD risk is more strongly established in the pharmacological literature than istradefylline's ICD warning.
• Option D: Option D is incorrect; simultaneous 50 percent reduction of all three agents at once prevents attribution of improvement to any specific agent and risks precipitating significant motor deterioration — one-agent-at-a-time or carefully staged de-escalation preserves the ability to understand what each change accomplished.
• Option E: Option E is incorrect; delaying medication adjustment pending psychiatric evaluation allows continued active harm from the gambling behavior — the pharmacological explanation for the ICD is sufficiently compelling to act on; psychiatric evaluation can proceed in parallel with medication de-escalation.

ANSWER: E

Rationale:

This question requires resisting the impulse to make additional medication changes at every visit and instead recognizing when the current trajectory justifies continued observation. Two important pharmacokinetic-pharmacodynamic principles apply here. First, pramipexole's reduction took effect over the past four weeks, but dopamine agonists can have prolonged pharmacodynamic effects that continue to evolve even after dose reduction — mesolimbic D3 receptor desensitization and normalization of reward circuit function may take additional weeks beyond the dose change, meaning residual hallucinations occurring once weekly may continue to improve without further intervention. Second, the dramatic resolution of gambling behavior confirms that pramipexole's D3 mesolimbic mechanism was the primary ICD driver — this also suggests that pramipexole was contributing meaningfully to the hallucinations, and further improvement can be expected as pramipexole's influence continues to wane. Making additional medication changes at this visit — reducing istradefylline, further reducing pramipexole, or adjusting Gocovri — before the effects of the current de-escalation have fully manifested would prevent accurate attribution of any further change in symptoms. The off-time increase to 2.5 hours is attributable to pramipexole reduction; istradefylline is likely attenuating a larger potential off-time increase, and maintaining it is rational. Option E correctly applies the principle of sequential de-escalation with adequate time intervals and preserves istradefylline while the effects of the current changes continue to evolve.

• Option A: Option A is incorrect; the increase in off-time from 1.5 to 2.5 hours after pramipexole reduction demonstrates that istradefylline is providing off-time benefit relative to what would be seen without it — interpreting 2.5 hours as evidence of no istradefylline benefit misunderstands the counterfactual.
• Option B: Option B is incorrect; the Gocovri dose reduction from 137 to 68.5 mg contributed to hallucination improvement — re-escalating would risk reversing this gain before the pramipexole effect has fully evolved.
• Option C: Option C is incorrect; complete pramipexole elimination at this visit, when the first 50 percent reduction is still taking effect, makes multiple simultaneous changes and eliminates a drug that provides meaningful dopaminergic tone — the one-change-at-a-time principle argues against this approach at this visit.
• Option D: Option D is incorrect; adding a levodopa tablet without allowing the current de-escalation to reach its steady state introduces a new variable; the off-time increase from pramipexole reduction is expected and can be reassessed after the full pharmacodynamic effect of the dose change has manifested.

ANSWER: B

Rationale:

This case concludes with the most clinically practical question: what does systematic, responsible long-term monitoring look like for a patient who has experienced and recovered from serious neuropsychiatric adverse effects on a three-agent adjunct regimen. Each element of the monitoring framework in Option B is pharmacologically justified. ICD screening at every visit is essential: this patient has a documented history of D3-mediated ICD from pramipexole that caused active financial harm — even at a reduced pramipexole dose, ongoing D3 stimulation of mesolimbic circuits continues to pose risk; additionally, istradefylline carries its own ICD warning as a Schedule V drug, and the combination of even low-level D3 agonism and A2A blockade creates a neuropsychiatric risk profile that cannot be considered fully resolved by the dose adjustments made. Validated ICD screening tools such as the QUIP-RS provide standardized surveillance that catches early behavioral changes before they cause harm. Neuropsychiatric review at every visit for hallucinations and nocturnal confusion is warranted because both amantadine ER and istradefylline remain in the regimen at therapeutic doses — they continue to carry hallucination risk, particularly in a patient with documented MCI. Renal function monitoring every six months is specifically required for amantadine ER: the patient's CrCl at the last measurement was 62 mL/min, above the dose-reduction threshold, but CKD is a dynamic condition and the CrCl threshold for dose adjustment (below 60 mL/min → 68.5 mg maximum; below 30 mL/min → contraindicated) can be crossed without symptoms. Annual cognitive reassessment documents the trajectory of MCI, distinguishes pharmacological from disease contributions, and provides a rational basis for future medication decisions. Option B correctly assembles all four monitoring obligations with their pharmacological justifications.

• Option A: Option A is incorrect; structured monitoring is not optional in a patient who has experienced serious neuropsychiatric adverse effects on multiple agents with ongoing exposure — the resolution of current symptoms does not eliminate future risk.
• Option C: Option C is incorrect; ongoing exposure to amantadine ER and istradefylline in a patient with MCI and a history of ICD makes neuropsychiatric monitoring essential, not elective.
• Option D: Option D is incorrect; istradefylline's Schedule V classification alone is not a sufficient reason for discontinuation when the drug is providing clinically meaningful off-time reduction — the Schedule V designation informs the monitoring obligation, not the prescribing decision.
• Option E: Option E is incorrect; liver function testing is not required as routine monitoring for istradefylline in patients without hepatic impairment — the renal monitoring for amantadine ER and the neuropsychiatric monitoring are the pharmacologically mandated elements; quarterly brain MRI for dopaminergic neurodegeneration assessment is not standard practice and is not indicated for amantadine ER dose adjustment.